XML 22 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net loss $ (52,146) $ (65,447)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities    
Depreciation and amortization 3,328 3,597
Amortization of lease right-of-use assets 2,179 2,247
Loss on extinguishment of liabilities, net   6,981
Share-based compensation expense 5,373 5,961
Change in fair value of warrant liability, net 1,274 (84)
Provision for doubtful accounts 497 93
Accrued interest, amortization of debt issuance costs and other 5,111 5,037
Inventory excess and obsolescence 166 906
Impairment loss on intangible assets 44 81
Changes in operating assets and liabilities:    
Accounts receivable (4,718) (1,501)
Other current assets 905 1,113
Other long-term assets 33 (3,504)
Accounts payable and other accrued liabilities 513 (773)
Deferred revenue (755) (1,213)
Contingent consideration (2,494)  
Tenant improvement allowances received 18,323 2,471
Current and long-term operating lease liabilities (503) (937)
Net cash and cash equivalents and restricted cash used in operating activities (22,870) (44,972)
Cash flows from investing activities    
Purchase of property and equipment (22,919) (3,298)
Patent costs and intangible asset acquisition, net (143) (236)
Net cash and cash equivalents and restricted cash used in investing activities (23,062) (3,534)
Cash flows from financing activities    
Proceeds from the issuance of common stock 28,126 59,538
Proceeds from issuance of common stock under employee stock purchase plan 643 355
Proceeds from exercise of stock options 91 269
Payment of contingent consideration (8,581) (10,822)
Proceeds from term loan and notes payable 10,000 45,102
Repayment of term loan and notes payable (49) (28,604)
Payment of debt issuance costs (833) (3,725)
Deferred offering costs   (129)
Equity financing costs (80) (3,069)
Other (188) (33)
Net cash and cash equivalents and restricted cash provided by financing activities 29,129 58,882
Net (decrease) increase in cash and cash equivalents and restricted cash (16,803) 10,376
Cash, cash equivalents, and restricted cash ‑ beginning of period 43,174 32,798
Cash, cash equivalents, and restricted cash ‑ end of period 26,371 43,174
Supplemental cash flow information:    
Common stock issued for deferred offering costs   600
Deferred offering costs amortized against Additional paid-in capital   75
Debt issuance costs included in accounts payable and other accrued liabilities 18 631
Equity financing costs included in accounts payable and other accrued liabilities 43 160
Issuance of Perceptive Warrants 674 3,051
Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842   1,269
Operating lease right-of-use assets obtained in exchange for lease liabilities 797 3,936
Finance lease right-of-use assets obtained in exchange for lease liabilities 773 123
Cash paid for interest 3,994 $ 1,009
Reclassification of warrant liability to additional paid-in capital 1,335  
Purchases of property & equipment included in accounts payable and accrued liabilities $ 793